Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Cindilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer

NCT05312840 | Unknown Phase 4

• 1 other identifier: 320.6750.2021-02-135
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

To observe the efficacy and safety of conventional and low-dose platinum Gemcitabine combined with Cindilimab with delayed administration in first-line treatment of advanced squamous non-small cell lung cancer.

Conditions

Non Small Cell Lung Cancer

Outcome Measures

Primary Outcomes (5)

• The objective response rate (ORR) of treatment was evaluated according to RECIST (v1.1).

  To evaluate the objective response rate (ORR) of subjects with advanced squamous non-small cell lung cancer treated with conventional and low-dose platinum Gemcitabine combined with Cindilimab with delayed administration in first-line treatment. ORR is defined as the proportion of subjects with complete response (CR) and partial response (PR) in the total subjects.

  36 months

• Assess the subject's progression free survival (PFS) according to RECIST (v1.1).

  To evaluate the progression free survival (PFS) of subjects with advanced squamous non-small cell lung cancer treated with conventional and low-dose platinum Gemcitabine combined with Cindilimab with delayed administration in first-line treatment. PFS is defined as the time from the beginning of treatment to the first imaging disease progression or death, whichever occurs first.

  36 months

• Assess the subject's disease control rate (DCR) according to RECIST (v1.1).

  To evaluate the disease control rate (DCR) of subjects with advanced squamous non-small cell lung cancer treated with conventional and low-dose platinum Gemcitabine combined with Cindilimab with delayed administration in first-line treatment. DCR is defined as the proportion of total subjects with complete remission (CR), partial remission (PR) and disease stability (SD).

  36 months

• The duration of remission (DOR) was assessed according to RECIST (v1.1).

  To evaluate the duration of remission (DOR) of subjects with advanced squamous non-small cell lung cancer treated with conventional and low-dose platinum Gemcitabine combined with Cindilimab with delayed administration in first-line treatment. DOR is defined as the time interval from the first recorded remission to disease progression or death, whichever occurs first.

  36 months

• The overall survival (OS) of the subjects was evaluated according to RECIST (v1.1).

  To evaluate the overall survival (OS) of subjects with advanced squamous non-small cell lung cancer treated with conventional and low-dose platinum Gemcitabine combined with Cindilimab with delayed administration in first-line treatment. OS is defined as the time from the beginning of treatment to the death of subjects from any cause.

  36 months

Secondary Outcomes (1)

• The incidence of adverse events was evaluated according to NCI CTCAE (v5.0).

  36 months

Study Arms (2)

Routine dose group

OTHER

Routine dose group: Every three weeks as a cycle. On the first day of each cycle, Gemcitabine 1000mg / m2, Cisplatin 75mg / m2, Carboplatin auc5 were injected intravenously, and Gemcitabine 1000mg / m2 and Cindilimab 200mg were injected intravenously on the eighth day. After 4 or 6 cycles of treatment, if there is no disease progression, continue to use Cindilimab 200mg every three weeks until the disease progresses.

Drug: Cisplatin / Carboplatin，Gemcitabine，Cindilimab

Low dose group

OTHER

Low dose group: Every three weeks as a cycle. Gemcitabine 750mg / m2, Cisplatin 56mg / m2 or Carboplatin auc3 were injected intravenously on the first day of each cycle 75. On the eighth day, Gemcitabine 750mg / m2 and Cindilimab 200mg were injected intravenously. After 4 or 6 cycles of treatment, if there is no disease progression, continue to use Cindilimab 200mg every three weeks until the disease progresses.

Drug: Cisplatin / Carboplatin，Gemcitabine，Cindilimab

Interventions

Cisplatin / Carboplatin，Gemcitabine，Cindilimab DRUG

1\. Routine dose group: Every three weeks as a cycle. On the first day of each cycle, Gemcitabine 1000mg / m2, Cisplatin 75mg / m2 / Carboplatin auc5 were injected intravenously, and Gemcitabine 1000mg / m2 and Cindilimab 200mg were injected intravenously on the eighth day; 2. Low dose group: every three weeks as a cycle. On the first day of each cycle, Gemcitabine 750mg / m2, Cisplatin 56mg / m2 / Carboplatin auc3 were injected intravenously 75. On the eighth day, Gemcitabine 750mg / m2 and Cindilimab 200mg were injected intravenously.

Low dose group; Routine dose group

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Sign written informed consent before implementing any test related process.
• Age ≥ 18 years old and ≤ 75 years old.
• Subjects with histologically or cytologically confirmed locally advanced (iiib-iiic), metastatic or recurrent (stage IV) squamous NSCLC (TNM lung cancer staging, 8th Edition, International Association for the study of lung cancer and Joint Committee on American Classification of cancer), inoperable and radical concurrent radiotherapy and chemotherapy, and who have not received systematic treatment before.
• The gene status is unknown, or the gene status of known histological specimens confirms that there is no EGFR gene sensitive mutation or ALK gene fusion mutation.
• According to the evaluation criteria of solid tumor efficacy (RECIST v1.1), at least one lesion can be measured by imaging. Lesions located in the radiation field of previous radiotherapy can be regarded as measurable lesions if they are confirmed to have progression.
• Have not received any systematic antitumor treatment for advanced / metastatic diseases in the past. Subjects who have previously received platinum containing adjuvant / neoadjuvant chemotherapy or radical chemoradiotherapy for advanced diseases, if the interval between disease progression or recurrence and the end of the last chemotherapeutic drug treatment is at least 6 months, are allowed to be included in this study.
• Subjects with brain metastases who are asymptomatic or have stable symptoms after local treatment are allowed to be included as long as they meet the following conditions: 1) measurable lesions outside the central nervous system, 2) no symptoms of the central nervous system or no aggravation of symptoms for at least 2 weeks, 3) no glucocorticoid treatment is required, or glucocorticoid treatment is stopped within 7 days before the first administration, Or the dosage of glucocorticoid is stable and reduced to less than 10mg / day prednisone (or equivalent dose) within 7 days before the first administration.
• Patients were allowed to receive palliative radiotherapy, but the end time of radiotherapy was 7 days before the administration of the first study drug, and the toxicity related to radiotherapy recovered to less than or equal to grade 1 (CTCAE V5.0).
• ECoG score: 0-1.
• Expected survival time \> 3 months.
• For adequate organ function, the subjects shall meet the following laboratory indexes: 1) the absolute value of neutrophils (ANC) ≥ 1.5x109/l without granulocyte colony stimulating factor in recent 14 days; 2) Platelets ≥ 100 without blood transfusion in recent 14 days × 109/L 3) Hemoglobin \> 9g / dl without blood transfusion or erythropoietin in recent 14 days; 4) Total bilirubin ≤ 1.5 times the upper limit of normal value (ULN) 5) aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are ≤ 2.5 times ULN (ALT or AST ≤ 5 is allowed for subjects with liver metastasis × ULN） 6) Serum creatinine ≤ 1.5 times ULN and creatinine clearance rate (calculated by Cockcroft Gault formula) ≥ 60 ml / min; 7) Good coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 times ULN; 8) Normal thyroid function is defined as thyroid stimulating hormone (TSH) within the normal range. If the baseline TSH is beyond the normal range, subjects with total T3 (or FT3) and FT4 within the normal range can also be enrolled; 9) The myocardial enzyme spectrum is within the normal range (for example, simple laboratory abnormalities that are not clinically significant according to the comprehensive judgment of the researcher are also allowed to be included in the group).
• For female subjects of childbearing age, urine or serum pregnancy test shall be conducted within 3 days before receiving the first study drug administration (day 1 of cycle 1) and the result is negative. If the urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is required. Women of non childbearing age are defined as having been postmenopausal for at least 1 year or having undergone surgical sterilization or hysterectomy.
• If there is a risk of pregnancy, all subjects (male or female) are required to use contraceptives with an annual failure rate of less than 1% throughout the treatment period until 120 days after the last study drug administration (or 180 days after the last study drug administration).

You may not qualify if:

• Pathology is adenocarcinoma or small cell lung cancer (SCLC), including lung cancer mixed with SCLC and NSCLC.
• Received radiotherapy before administration of the first study drug, Meet one of the following conditions: 1) more than 30% of bone marrow had received radiotherapy within 14 days before treatment; 2) received radiotherapy for lung lesions within 6 weeks before treatment and the dose was \> 30Gy (the enrolled subjects must recover from the toxicity of previous radiotherapy to grade 1 or below, do not need glucocorticoid treatment and have no history of radiation pneumonia) 3) The end time of palliative radiotherapy was within 7 days before the administration of the first study drug.
• Other malignant diseases other than NSCLC diagnosed within 5 years before the first administration (excluding radical skin basal cell carcinoma, skin squamous epithelial carcinoma, and / or radical resection of carcinoma in situ).
• Currently participating in intervention clinical research treatment, or receiving other research drugs or using research instruments within 4 weeks before the first administration.
• Previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or drugs that stimulate or co inhibit T cell receptors (e.g., CTLA-4, OX-40, CD137).
• Received systemic treatment with Chinese patent medicine with anti NSCLC indications or drugs with immunomodulatory effect (including thymosin, interferon and interleukin, except for local use to control pleural effusion) within 2 weeks before the first administration.
• Active autoimmune diseases requiring systemic treatment (such as the use of disease relief drugs, glucocorticoids or immunosuppressants) occurred within 2 years before the first administration. Alternative therapies (such as thyroxine, insulin or physiological glucocorticoids for adrenal or pituitary insufficiency) are not considered systemic treatment.
• Being treated with systemic glucocorticoids (excluding nasal spray, inhaled or other local glucocorticoids) or any other form of immunosuppressive therapy within 7 days before the first administration of the study; Note: it is allowed to use glucocorticoids in physiological doses (≤ 10 mg / day prednisone or equivalent).
• There is clinically uncontrollable pleural effusion / peritoneal effusion (subjects who do not need to drain effusion or stop drainage for 3 days and have no significant increase in effusion can be enrolled).
• Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation.
• Those who are known to be allergic to active ingredients or excipients such as cindilimab, pemetrexed, gemcitabine, carboplatin and cisplatin.
• Not fully recovered from toxicity and / or complications caused by any intervention before starting treatment (i.e. ≤ grade 1 or reaching baseline, excluding fatigue or hair loss).
• Known history of human immunodeficiency virus (HIV) infection (i.e. HIV 1 / 2 antibody positive).
• untreated active hepatitis B (defined as HBsAg positive and HBV-DNA copy number at the same time was higher than the upper limit of normal value in the laboratory of the research center). Note: hepatitis B patients who met the following criteria can also be admitted into the group: 1) HBV viral load \<1000 copy /ml (200 IU/ml) before the first dose, the subjects should receive anti HBV therapy to avoid reactivation of the virus during the whole course of chemotherapy (2). Subjects with anti HBc (+), HBsAg (-), anti HBs (-) and HBV viral load (-), Prophylactic anti HBV treatment is not required, but virus reactivation needs to be closely monitored.
• Active HCV infected subjects (HCV antibody positive and HCV-RNA level above the lower limit of detection).

Sponsors & Collaborators

• People's Hospital of Quzhou: lead

Study Sites (1)

Quzhou people's Hospital

Quzhou, Zhejiang, China

RECRUITING

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

Cisplatin

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Chlorine Compounds; Inorganic Chemicals; Nitrogen Compounds; Platinum Compounds

Study Officials

• Xuru Jin

  People's Hospital of Quzhou

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Xuru Jin

CONTACT

13857782369; hjh2018hjh@163.com

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: chief physician

Study Record Dates

• First Submitted: March 14, 2022
• First Posted: April 6, 2022
• Study Start: January 1, 2022
• Primary Completion: December 31, 2024
• Study Completion: December 31, 2024
• Last Updated: April 6, 2022

Record last verified: 2022-04

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)